Lopid and Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Tablets
Determining the interaction of Lopid and Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Tablets and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Using dasabuvir together with gemfibrozil is not recommended. Combining these medications may significantly increase the blood levels of dasabuvir, one of the components of your hepatitis C medication. This may increase the risk of side effects such as irregular heart rhythm and liver problems. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:CONTRAINDICATED: Coadministration with potent inhibitors of CYP450 2C8 may significantly increase the plasma concentrations of dasabuvir, which is primarily metabolized by the isoenzyme. When a single dose of dasabuvir was administered to 11 study subjects treated with the potent CYP450 2C8 inhibitor gemfibrozil at 600 mg twice daily, dasabuvir peak plasma concentration (Cmax) and systemic exposure (AUC) increased by approximately 2- and 11-fold, respectively. Elevated plasma levels of dasabuvir may increase the risk of QT prolongation according to the manufacturer.
MANAGEMENT: Concomitant use of dasabuvir with potent CYP450 2C8 inhibitors is considered contraindicated.
- "Product Information. Viekira Pak (dasabuvir/ombitasvir/paritaprevir/ritonavir)." AbbVie US LLC, North Chicago, IL.
- Ogilvie BW, Zhang D, Li W, et al. "Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions." Drug Metab Dispos 34 (2006): 191-7
- Tornio A, Filppula A, Kailari O, et al. "Glucuronidation converts clopidogrel to a strong time-dependent inhibitor of CYP2C8 a phase 2 metabolite as perpetrator of drug-drug interactions." Clin Pharmacol Ther (2014):
Generic Name: dasabuvir / ombitasvir / paritaprevir / ritonavir
Brand name: Viekira XR, Viekira Pak
Synonyms: Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets, and Dasabuvir
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Lopid-Omeclamox-Pak
- Lopid-Omega-3 Fatty Acid Capsules
- Lopid-Omega-3 Fatty Acids
- Lopid-Omega-3 polyunsaturated fatty acids
- Lopid-Omega-3-acid ethyl esters
- Lopid-Omega-3-carboxylic acids
- Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Tablets-Lopinavir and ritonavir
- Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Tablets-Lopinavir and Ritonavir Oral Solution
- Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Tablets-Lopinavir and Ritonavir Solution
- Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Tablets-Lopinavir and Ritonavir Tablets
- Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Tablets-Lopreeza
- Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Tablets-Lopressor